Adma to price initial public offering of stock between $8.50 and $9.50

Bookrunner Oppenheimer could sell 2,666,667 shares with greenshoe

By Devika Patel

Knoxville, Tenn., Sept. 25 - Adma Biologics, Inc. will price its initial public sale of common stock at a price between $8.50 and $9.50 per share, increased from between $8.00 and $9.00 per share, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission. The deal was announced on April 11.

The company will sell 2,666,667 shares with a 30-day greenshoe of an additional 400,000 shares.

Oppenheimer & Co. is the bookrunning manager. Ladenburg Thalmann & Co. Inc., Maxim Group LLC and Laidlaw & Co. (UK) Ltd. are the co-managers.

Proceeds will be used to continue clinical testing and commercialization of RI-002 and for working capital and other general corporate purposes.

The Tampa-based company is the developer and administrator of web-based individual health insurance plans and ancillary products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.